Cargando…

Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment

OBJECTIVE: The treatment of patients with differentiated thyroid cancer (DTC) was modified in the last decade towards a more individualized approach according to the risk of recurrence (RR). We compared the outcomes of patients with low and intermediate RR (LRR and IRR) who received or did not recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Abelleira, Erika, Peñaloza, Mirna Angela, Jerkovich, Fernando, Bueno, Fernanda, Pitoia, Fabián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Endocrinologia e Metabologia 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065346/
https://www.ncbi.nlm.nih.gov/pubmed/34731559
http://dx.doi.org/10.20945/2359-3997000000374
_version_ 1785018088533524480
author Abelleira, Erika
Peñaloza, Mirna Angela
Jerkovich, Fernando
Bueno, Fernanda
Pitoia, Fabián
author_facet Abelleira, Erika
Peñaloza, Mirna Angela
Jerkovich, Fernando
Bueno, Fernanda
Pitoia, Fabián
author_sort Abelleira, Erika
collection PubMed
description OBJECTIVE: The treatment of patients with differentiated thyroid cancer (DTC) was modified in the last decade towards a more individualized approach according to the risk of recurrence (RR). We compared the outcomes of patients with low and intermediate RR (LRR and IRR) who received or did not receive radioiodine remnant ablation (RRA) after assessing the dynamic risk. MATERIALS AND METHODS: We included 307 DTC patients with LRR and IRR submitted to total thyroidectomy. All patients were reclassified according to the dynamic risk stratification (low or high). Patients with high dynamic risk received RRA (141 patients). RESULTS: LRR patients who received RRA presented a frequency of structural incomplete response (SIR) of 5% at the end of the follow-up, compared to 2% in those who did not receive it (p=0.353). IRR patients treated with RRA had a frequency of SIR of 22%, compared to 5% in patients without RRA (p=0.008). CONCLUSIONS: This study demonstrates the usefulness of dynamic risk assessment to decide RRA in a cohort with a long-term follow-up. The lower prevalence of SIR at the end of the follow-up in patients who did not receive RRA highlights the adequate selection of those who would not benefit from RRA, even with an intermediate risk of recurrence.
format Online
Article
Text
id pubmed-10065346
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Sociedade Brasileira de Endocrinologia e Metabologia
record_format MEDLINE/PubMed
spelling pubmed-100653462023-04-01 Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment Abelleira, Erika Peñaloza, Mirna Angela Jerkovich, Fernando Bueno, Fernanda Pitoia, Fabián Arch Endocrinol Metab Original Article OBJECTIVE: The treatment of patients with differentiated thyroid cancer (DTC) was modified in the last decade towards a more individualized approach according to the risk of recurrence (RR). We compared the outcomes of patients with low and intermediate RR (LRR and IRR) who received or did not receive radioiodine remnant ablation (RRA) after assessing the dynamic risk. MATERIALS AND METHODS: We included 307 DTC patients with LRR and IRR submitted to total thyroidectomy. All patients were reclassified according to the dynamic risk stratification (low or high). Patients with high dynamic risk received RRA (141 patients). RESULTS: LRR patients who received RRA presented a frequency of structural incomplete response (SIR) of 5% at the end of the follow-up, compared to 2% in those who did not receive it (p=0.353). IRR patients treated with RRA had a frequency of SIR of 22%, compared to 5% in patients without RRA (p=0.008). CONCLUSIONS: This study demonstrates the usefulness of dynamic risk assessment to decide RRA in a cohort with a long-term follow-up. The lower prevalence of SIR at the end of the follow-up in patients who did not receive RRA highlights the adequate selection of those who would not benefit from RRA, even with an intermediate risk of recurrence. Sociedade Brasileira de Endocrinologia e Metabologia 2021-04-29 /pmc/articles/PMC10065346/ /pubmed/34731559 http://dx.doi.org/10.20945/2359-3997000000374 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Abelleira, Erika
Peñaloza, Mirna Angela
Jerkovich, Fernando
Bueno, Fernanda
Pitoia, Fabián
Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment
title Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment
title_full Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment
title_fullStr Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment
title_full_unstemmed Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment
title_short Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment
title_sort dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065346/
https://www.ncbi.nlm.nih.gov/pubmed/34731559
http://dx.doi.org/10.20945/2359-3997000000374
work_keys_str_mv AT abelleiraerika dynamicriskallowsustoadequatelyselectpatientswithdifferentiatedthyroidcancerwhodonotrequireradioiodinetreatment
AT penalozamirnaangela dynamicriskallowsustoadequatelyselectpatientswithdifferentiatedthyroidcancerwhodonotrequireradioiodinetreatment
AT jerkovichfernando dynamicriskallowsustoadequatelyselectpatientswithdifferentiatedthyroidcancerwhodonotrequireradioiodinetreatment
AT buenofernanda dynamicriskallowsustoadequatelyselectpatientswithdifferentiatedthyroidcancerwhodonotrequireradioiodinetreatment
AT pitoiafabian dynamicriskallowsustoadequatelyselectpatientswithdifferentiatedthyroidcancerwhodonotrequireradioiodinetreatment